Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Patients w/ CAR-HEMATOTOX ≥3 or Endothelial Activation and Stress Index >median have increased risk prolonged hospitalization, antibiotic tx and fever during step-up dosing + cytopenias, severe infections, inferior outcomes.”
Title: Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Authors: Jan Frenking, Christine Riedhammer, Thomas Hielscher, Christoph Schaefers, Lisa Leypoldt, Marie Harzer, David Sedloev, Valentine Landrin, Niklas Kehl, Mirco Friedrich, Xiang Zhou, Maximilian Steinhardt, Philipp Weis, Julia Mersi, Johannes Waldschmidt, Niels Weinhold, Martin Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Katja Weisel, Tim Richardson, Raphael Teipel, Leo Rasche, Marc Raab
You can read the Full Article in Blood Cancer Discovery.
You can find more posts featuring Robert Orlowski on OncoDaily.
